Skip to main content
Top
Published in: Infectious Diseases and Therapy 3/2016

Open Access 01-09-2016 | Original Research

Molecular Characterization of Invasive Carbapenem-Resistant Acinetobacter baumannii from a Tertiary Care Hospital in South India

Authors: Saranya Vijayakumar, Radha Gopi, Priya Gunasekaran, Manjurekar Bharathy, Kamini Walia, Shalini Anandan, Balaji Veeraraghavan

Published in: Infectious Diseases and Therapy | Issue 3/2016

Login to get access

Abstract

Introduction

Acinetobacter baumannii is an important opportunistic pathogen responsible for causing nosocomial infections. Carbapenems are considered to be the drug of choice to treat infections caused by multidrug-resistant A. baumannii. The prevalent mechanism of carbapenem resistance in A. baumannii is enzymatic degradation by β-lactamases. Therefore, the aim of the study is to determine the prevalence and distribution of molecular determinants among the clinical isolates of carbapenem-resistant A. baumannii.

Methods

A total of 103 consecutive, non-duplicate carbapenem-resistant A. baumannii isolated from blood and endotracheal aspirates (ETAs) were included in the study. The CarbAcineto NP test was performed for the screening of carbapenemase production. Polymerase chain reaction (PCR) was performed to detect extended spectrum β-lactamases (ESBLs), metallo-β-lactamases (MBLs) and oxacillinases (OXAs). PCR was done for the detection of ISAba1 elements, and mapping PCR was performed to identify the position of ISAba1 with respect to the OXA-23-like gene.

Results

Among the 103 A. baumannii isolates, 94 were phenotypically identified as carbapenemase producers. blaPER was the most common among the ESBLs. Among MBLs, blaNDM was predominant followed by the blaVIM gene. blaOXA-51 and blaOXA-23 were the most common and present in all 103 isolates. Almost 80% of the isolates had ISAba1 upstream blaOXA-23 gene.

Conclusion

The blaOXA-23 and blaNDM genes are the most common type of oxacillinases and metallo β-lactamases, respectively, and contribute to carbapenem resistance in clinical isolates of A. baumannii. The presence of ISAba1 upstream of the blaOXA-23 gene suggests that the insertion element acts as a promoter for its increased expression.

Funding

Indian Council of Medical Research, New Delhi, India (ref. no. AMR/TF/54/13ECDHII dated 23 October 2013).
Literature
1.
go back to reference Abbott Iain, Cerqueira GM, Bhuiyan S, Peleg AY. Carbapenem resistance in Acinetobacter. Laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev Anti Infect Ther. 2013;11(4):395–409.CrossRefPubMed Abbott Iain, Cerqueira GM, Bhuiyan S, Peleg AY. Carbapenem resistance in Acinetobacter. Laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev Anti Infect Ther. 2013;11(4):395–409.CrossRefPubMed
2.
go back to reference Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5:939–51.CrossRefPubMed Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5:939–51.CrossRefPubMed
3.
go back to reference Roca I, Espinal P, Vila-Farrés X, Vila J. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Front Microbiol. 2012;3:Article 148.CrossRefPubMed Roca I, Espinal P, Vila-Farrés X, Vila J. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Front Microbiol. 2012;3:Article 148.CrossRefPubMed
4.
go back to reference Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–36.CrossRefPubMed Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–36.CrossRefPubMed
5.
go back to reference Kim UJ, Kim HK, An JH, Cho SK, Park K-H, Jang H-C. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J. 2014;50(2):37.CrossRefPubMedPubMedCentral Kim UJ, Kim HK, An JH, Cho SK, Park K-H, Jang H-C. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J. 2014;50(2):37.CrossRefPubMedPubMedCentral
6.
go back to reference Turton JF, Ward E, Woodford N, Kaufmann ME, Pike R, Livermore DM, Pitt TL. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006;258:72–7.CrossRefPubMed Turton JF, Ward E, Woodford N, Kaufmann ME, Pike R, Livermore DM, Pitt TL. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006;258:72–7.CrossRefPubMed
7.
go back to reference Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol. 2006;44(8):2974–6.CrossRefPubMedPubMedCentral Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol. 2006;44(8):2974–6.CrossRefPubMedPubMedCentral
8.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty second informational supplement M100–S22. Wayne: CLSI; 2014. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty second informational supplement M100–S22. Wayne: CLSI; 2014.
9.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty second informational supplement M100–S22. Wayne: CLSI; 2015. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty second informational supplement M100–S22. Wayne: CLSI; 2015.
10.
go back to reference Dortet L, Poirel L, Errera C, Nordmann P. Carbacineto NP test for rapid detection of carbapenemase-producers in Acinetobacter spp. J Clin Microbiol. 2014. doi:10.1128/JCM.00594-14. Dortet L, Poirel L, Errera C, Nordmann P. Carbacineto NP test for rapid detection of carbapenemase-producers in Acinetobacter spp. J Clin Microbiol. 2014. doi:10.​1128/​JCM.​00594-14.
11.
go back to reference Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important b-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010;65:490–5.CrossRefPubMed Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important b-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010;65:490–5.CrossRefPubMed
12.
go back to reference Lascols C, Hackel M, Marshall SH, et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother. 2011;9:1992–7.CrossRef Lascols C, Hackel M, Marshall SH, et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother. 2011;9:1992–7.CrossRef
13.
go back to reference Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing betalactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151–61.CrossRefPubMedPubMedCentral Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing betalactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151–61.CrossRefPubMedPubMedCentral
14.
go back to reference Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70:119–23.CrossRefPubMed Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70:119–23.CrossRefPubMed
15.
go back to reference Woodford Neil, Ellington Matthew J, Coelho Juliana M, Turton Jane F, Elaina Ward M, Brown Susan, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351–3.CrossRefPubMed Woodford Neil, Ellington Matthew J, Coelho Juliana M, Turton Jane F, Elaina Ward M, Brown Susan, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351–3.CrossRefPubMed
16.
go back to reference Segal H, Garny S, Elisha BG. Is ISABA-1 customized for Acinetobacter? FEMS Microbiol Lett. 2005;243:425–9.CrossRefPubMed Segal H, Garny S, Elisha BG. Is ISABA-1 customized for Acinetobacter? FEMS Microbiol Lett. 2005;243:425–9.CrossRefPubMed
18.
go back to reference Kamolvit W, Sidjabat HE, Paterson DL. Molecular epidemiology and mechanisms of carbapenem resistance of Acinetobacter spp. in Asia and Oceania. Microb Drug Resist. 2015;21(4):424–34.CrossRefPubMed Kamolvit W, Sidjabat HE, Paterson DL. Molecular epidemiology and mechanisms of carbapenem resistance of Acinetobacter spp. in Asia and Oceania. Microb Drug Resist. 2015;21(4):424–34.CrossRefPubMed
19.
go back to reference Saranathan R, Vasanth V, Vasanth T, Shabareesh PRV, Shashikala P, Devi CS, et al. Emergence of carbapenem non-susceptible multidrug resistant Acinetobacter baumannii strains of CC 103B and CC 92B clonal complexes harboring OXA-type carbapenemases and metallo-β-lactamases in Southern India. Microbiol Immunol. 2015;59(5):277–84.CrossRefPubMed Saranathan R, Vasanth V, Vasanth T, Shabareesh PRV, Shashikala P, Devi CS, et al. Emergence of carbapenem non-susceptible multidrug resistant Acinetobacter baumannii strains of CC 103B and CC 92B clonal complexes harboring OXA-type carbapenemases and metallo-β-lactamases in Southern India. Microbiol Immunol. 2015;59(5):277–84.CrossRefPubMed
20.
go back to reference Amudhan SM, Sekar U, Arunagiri K, Sekar B. OXA beta-lactamase-mediated carbapenem resistance in Acinetobacter baumannii. Indian J Med Microbiol. 2011;29(3):269–74.CrossRefPubMed Amudhan SM, Sekar U, Arunagiri K, Sekar B. OXA beta-lactamase-mediated carbapenem resistance in Acinetobacter baumannii. Indian J Med Microbiol. 2011;29(3):269–74.CrossRefPubMed
22.
go back to reference Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 Carbapenemase Gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16(1):35–40.CrossRefPubMedPubMedCentral Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 Carbapenemase Gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16(1):35–40.CrossRefPubMedPubMedCentral
23.
go back to reference Evans BA, Hamouda A, Amyes SGB. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des. 2013;19:223–38.CrossRefPubMed Evans BA, Hamouda A, Amyes SGB. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des. 2013;19:223–38.CrossRefPubMed
24.
go back to reference Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49(8):3198–202.CrossRefPubMedPubMedCentral Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49(8):3198–202.CrossRefPubMedPubMedCentral
Metadata
Title
Molecular Characterization of Invasive Carbapenem-Resistant Acinetobacter baumannii from a Tertiary Care Hospital in South India
Authors
Saranya Vijayakumar
Radha Gopi
Priya Gunasekaran
Manjurekar Bharathy
Kamini Walia
Shalini Anandan
Balaji Veeraraghavan
Publication date
01-09-2016
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 3/2016
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-016-0125-y

Other articles of this Issue 3/2016

Infectious Diseases and Therapy 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.